Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

non-metastatic prostate cancer

- PMLiVE

Pfizer’s Inlyta gets EU approval for advanced kidney cancer

Available as second-line therapy after treatment with pharma firm's own Sutent

Astellas wins US approval for prostate cancer drug Xtandi

Pharma company and its partner Medivation gain FDA licence for type of late-stage prostate cancer

- PMLiVE

Astellas Pharma Europe appoint new senior director, market access

Dr Susan Wood was previously senior brand director of the company’s pain management franchise 

- PMLiVE

Pfizer dealt another blow as Torisel fails kidney cancer trial

Results are another setback in company's bid to extend the indications for its mTOR inhibitor

- PMLiVE

End of the line for intravenous bapineuzumab in Alzheimer’s

Negative trial results for Pfizer and Johnson & Johnson to concede defeat

Astellas to close US urology research facility

Work at Urogenix, North Carolina site will end by the end of the year

- PMLiVE

Pfizer sells Kent R&D centre to property consortium

Discovery Park Ltd takes over site 18 months after US pharma firm announced plans to exit it

- PMLiVE

Interview: Yoshihiko Hatanaka, CEO and president, Astellas

The president and CEO of Astellas Pharma tells Jacky Law how he intends to steer the company through the current economic downturn

- PMLiVE

Interview: Ken Jones, Astellas Pharma Europe

The president and CEO of Astellas Pharma Europe talks to Liz Wells about beating the economic downturn and the experience of working for a Japanese company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links